Literature DB >> 12504791

Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight.

Luca Parente1, Mauro Perretti.   

Abstract

The aim of this commentary is to discuss recent data on the role of prostaglandins generated by both constitutive and inducible cyclooxygenases (COXs). According to a popular hypothesis, COX-1 generates 'good' prostaglandins for physiological 'housekeeping' functions like gastrointestinal (GI) mucosal integrity and regulation of renal blood flow, while COX-2 forms the 'bad' prostaglandins responsible for inflammatory symptoms. However, recent data show that the biological functions of prostanoids formed by the two enzymes are much more complex and interrelated than previously appreciated. Experimental evidence indicates that a full inflammatory response is likely sustained by prostanoids generated by both enzymes, and an effective anti-inflammatory effect requires the inhibition of the two enzymes. Similarly, the selective inhibition of either COX-1 or COX-2 does not elicit GI damage, but inhibition of both enzymes is necessary for GI mucosal damage to develop. Prostaglandins generated by both enzymes contribute to normal renal function by regulating the vascular tone and the normal blood flow. The synthesis of endothelial prostacyclin is mainly driven by COX-2, so that the selective COX-2 inhibition may bias vascular prostaglandin synthesis in favour of COX-1-derived thromboxane A(2) in platelets, leading to a prothrombotic outcome. Moreover, prostaglandins formed by COX-2 appear to have a major role in myocardial protection. We propose that the complexity of the situation in the field of COX-derived mediators should be borne in mind when anti-inflammatory therapy is required.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12504791     DOI: 10.1016/s0006-2952(02)01422-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  35 in total

1.  Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins.

Authors:  Noriyuki Omura; Margaret Griffith; Audrey Vincent; Ang Li; Seung-Mo Hong; Kimberly Walter; Michael Borges; Michael Goggins
Journal:  Mol Cancer Res       Date:  2010-06-08       Impact factor: 5.852

2.  Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.

Authors:  Arduino A Mangoni; Richard J Woodman; Paraskevi Gaganis; Andrew L Gilbert; Kathleen M Knights
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

3.  In vivo imaging of zebrafish digestive organ function using multiple quenched fluorescent reporters.

Authors:  Kotaro Hama; Elayne Provost; Timothy C Baranowski; Amy L Rubinstein; Jennifer L Anderson; Steven D Leach; Steven A Farber
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-12-04       Impact factor: 4.052

Review 4.  Bioactive lipids in Trypanosoma cruzi infection.

Authors:  Fabiana S Machado; Shankar Mukherjee; Louis M Weiss; Herbert B Tanowitz; Anthony W Ashton
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

5.  Effect of age and COX-2-derived prostanoids on the progression of adult vascular dysfunction in the offspring of diabetic rats.

Authors:  F E Ramos-Alves; D B de Queiroz; J Santos-Rocha; G P Duarte; F E Xavier
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

6.  IgE, COX-2, and IL-4 are expressed by DEHP through p38 MAPK and suppressed by plant glycoprotein (75 kDa) in ICR mice.

Authors:  Phil-Sun Oh; Kye-Taek Lim
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

7.  Alteration of renal cyclooxygenase expression due to partial unilateral ureteral obstruction in neonatal.

Authors:  Zhi Qin Li; Yi Zhang; Qi Li; Shu Huan Wu; Chang Yu Sun; Zu Jiang Yu
Journal:  Can Urol Assoc J       Date:  2013-03-21       Impact factor: 1.862

8.  Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes.

Authors:  Anna R Ciccaglione; Emilia Stellacci; Cinzia Marcantonio; Valentina Muto; Michele Equestre; Giulia Marsili; Maria Rapicetta; Angela Battistini
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

Review 9.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

10.  Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations.

Authors:  Svenja D Steinbrink; Carlo Pergola; Ulrike Bühring; Sven George; Julia Metzner; Astrid S Fischer; Ann-Kathrin Häfner; Joanna M Wisniewska; Gerd Geisslinger; Oliver Werz; Dieter Steinhilber; Thorsten J Maier
Journal:  Cell Mol Life Sci       Date:  2009-11-29       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.